Welcome to our dedicated page for Hinge Health news (Ticker: HNGE), a resource for investors and traders seeking the latest updates and insights on Hinge Health stock.
Hinge Health, Inc. (NYSE: HNGE) is a health information services company focused on automating and scaling healthcare delivery for musculoskeletal (MSK) conditions. Its news flow centers on developments in digital MSK care, AI-powered technology, financial performance, and corporate actions that matter to investors, employers, and health plans.
Company announcements regularly highlight financial results and guidance, including quarterly earnings releases that discuss revenue trends, margins, cash flows, and key operating metrics such as calculated billings and client counts. These earnings updates are often accompanied by details on non-GAAP financial measures and information about investor webcasts and conference calls.
Hinge Health also issues news about its AI-powered care model and product capabilities. Examples include the introduction of Movement Analysis, which uses TrueMotion computer vision technology to track joint health, and Robin, an AI Care Assistant that offers 24/7 support and helps clinicians respond to pain flare-ups. Additional product-related news has covered the launch of HingeSelect, a high-performance MSK provider network that integrates digital exercise therapy with in-person care from curated local providers.
Another important category of news involves clinical and economic outcomes. The company has announced peer-reviewed studies and medical claims analyses that examine imaging utilization, surgery rates, and cost savings for members using its digital MSK platform. These releases often describe how evidence-based digital care can reduce unnecessary imaging, procedures, and overall MSK-related spending.
Corporate and capital markets updates, such as the authorization of a share repurchase program and information related to its IPO and lock-up agreements, also appear in Hinge Health’s news. For ongoing coverage of HNGE, this page aggregates press releases and related updates so readers can follow the company’s financial disclosures, product innovations, and research findings over time.
Hinge Health (NYSE: HNGE) reported strong Q2 2025 financial results, with revenue surging 55% year-over-year to $139.1 million. The company demonstrated robust growth metrics, including a 32% increase in client base to 2,359 and LTM calculated billings of $568.4 million, up 55% from Q2 2024.
The company's financial performance showed mixed results, with a GAAP loss from operations of $580.7 million, largely due to $591.0 million in stock-based compensation expense. However, non-GAAP income from operations was positive at $26.1 million. The company maintained strong liquidity with $415.1 million in cash and equivalents.
Looking ahead, Hinge Health provided guidance for Q3 2025 with expected revenue between $141-143 million and full-year 2025 revenue projected at $548-552 million, representing 41% year-over-year growth at the midpoint.
Hinge Health (NYSE:HNGE) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close. The company will host an earnings conference call at 1:30 PM PT / 4:30 PM ET on the same day to discuss its quarterly performance and provide guidance.
Investors can access the live audio webcast through the company's investor relations website at ir.hingehealth.com. A replay of the webcast will be made available on the website following the presentation.
Hinge Health (NYSE: HNGE) has announced the pricing of its Initial Public Offering (IPO), offering 13,666,000 shares of Class A common stock at $32.00 per share. The offering consists of 8,522,528 shares from Hinge Health and 5,143,472 shares from selling stockholders. Trading is set to begin on the NYSE on May 22, 2025, under the ticker "HNGE".
The selling stockholders have granted underwriters a 30-day option to purchase up to 2,049,900 additional shares. The company plans to use the proceeds primarily to cover tax obligations related to restricted stock units. Morgan Stanley, Barclays, and BofA Securities are serving as lead book-running managers for the offering.